Vaccines with MF59 Adjuvant Expand the Antibody Repertoire to Target Protective Sites of Pandemic Avian H5N1 Influenza Virus-Reference-Cited by-同舟云学术

Vaccines with MF59 Adjuvant Expand the Antibody Repertoire to Target Protective Sites of Pandemic Avian H5N1 Influenza Virus

Published:2010-01-20 Issue:15 Volume:2 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Khurana Surender¹,Chearwae Wanida¹,Castellino Flora²,Manischewitz Jody¹,King Lisa R.¹,Honorkiewicz Agnieszka¹,Rock Michael T.³,Edwards Kathryn M.³,Del Giudice Giuseppe²,Rappuoli Rino²,Golding Hana¹

Affiliation:

1. Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA.

2. Novartis Vaccines and Diagnostics Research Center, Siena 53100, Italy.

3. Division of Pediatric Infectious Diseases, Vanderbilt University Medical Center, Nashville, TN 37232, USA.

Abstract

An oil-based adjuvant improves the efficacy of an H5N1 vaccine by inducing antibodies against additional sites on influenza surface proteins.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference17 articles.

1. Antigenic and Genetic Characteristics of Swine-Origin 2009 A(H1N1) Influenza Viruses Circulating in Humans

2. Emergence of European Avian Influenza Virus-Like H1N1 Swine Influenza A Viruses in China

3. Safety and Immunogenicity of an Inactivated Subvirion Influenza A (H5N1) Vaccine

4. Safety and Immunogenicity of Multiple and Higher Doses of an Inactivated Influenza A/H5N1 Vaccine

5. Development and evaluation of influenza pandemic vaccines

Cited by 235 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An Overview of the Types of Adjuvants Used in the Vaccination Industry And Their Mechanisms of Action;Viral Immunology;2024-08-22

2. Licensed H5N1 vaccines generate cross-neutralizing antibodies against highly pathogenic H5N1 clade 2.3.4.4b influenza virus;Nature Medicine;2024-07-16

3. Lipid Nanoparticle with 1,2-Di-O-octadecenyl-3-trimethylammonium-propane as a Component Lipid Confers Potent Responses of Th1 Cells and Antibody against Vaccine Antigen;ACS Nano;2024-06-17

4. Differential Regulation of DC Function, Adaptive Immunity, and MyD88 Dependence by MF59 and AS03-like Adjuvants;Vaccines;2024-05-13

5. Flublok Quadrivalent Vaccine Adjuvanted with R-DOTAP Elicits a Robust and Multifunctional CD4 T Cell Response That Is of Greater Magnitude and Functional Diversity Than Conventional Adjuvant Systems;Vaccines;2024-03-07